Description
Ilumetri tildrakizumab 100 mg is a prescription biologic medicine supplied as a single-use prefilled syringe containing 100 mg of tildrakizumab in 1 mL. It is approved for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. This guide explains the approved use, dosing schedule, infection checks, injection technique, side effects and storage rules in practical language.
Ilumetri tildrakizumab: quick facts
- Active ingredient: tildrakizumab 100 mg/1 mL.
- Medicine type: humanised monoclonal antibody and selective IL-23 p19 inhibitor.
- Approved use: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
- Route: subcutaneous injection.
- Usual schedule: Week 0, Week 4, then every 12 weeks.
- Supply: single-use prefilled syringe; prescription only.
How Ilumetri tildrakizumab works
Psoriasis is driven partly by an overactive immune pathway involving interleukin-23, or IL-23. Tildrakizumab binds selectively to the p19 subunit of IL-23 and blocks its interaction with the IL-23 receptor. This reduces inflammatory signalling that contributes to raised, red and scaly plaques. It is not a steroid and it does not cure psoriasis, but sustained treatment can improve skin clearance and disease control.
Who may be prescribed Ilumetri?
A dermatologist may consider Ilumetri tildrakizumab when an adult has moderate-to-severe plaque psoriasis and needs systemic treatment. The prescriber reviews disease severity, previous therapies, infection history, tuberculosis risk, vaccination status, other medicines and pregnancy plans before treatment. It should not be started during a clinically important active infection, including active tuberculosis.
Approved dosing schedule
The recommended dose is 100 mg injected under the skin at Week 0 and Week 4, followed by 100 mg every 12 weeks. For patients with certain characteristics, such as a high disease burden or body weight of 90 kg or more, the physician may consider 200 mg. The prescribing specialist decides whether that alternative is appropriate; patients must never double the dose themselves.
Response should be reviewed over time. If there is no response after 28 weeks, the physician may consider stopping treatment. If a dose is missed, administer it as soon as possible after speaking with the healthcare team, then continue the planned schedule from the appropriate date. Do not use two doses together to compensate.
How to prepare and inject safely
- Keep the syringe in its carton and remove it from the refrigerator about 30 minutes before injection.
- Do not shake, freeze, heat or expose the syringe to direct sunlight.
- Check the expiry date and solution. Do not use it if the liquid is cloudy, contains visible particles or is distinctly brown.
- Wash and dry your hands. Clean the chosen site as instructed and allow it to dry.
- Inject into the abdomen or thigh, or into the upper arm when administered by a caregiver or healthcare professional.
- Rotate sites. Avoid skin that is affected by psoriasis, tender, bruised, red, hard, thick or scaly.
- Use each syringe once and dispose of it in an approved sharps container.
Patients may self-inject Ilumetri tildrakizumab only after appropriate training and when the healthcare professional considers self-administration suitable. Always follow the device instructions supplied with the pack.
7 essential safety checks
1. Active infection
Tell the prescriber about fever, persistent cough, painful skin, urinary symptoms or any infection that is ongoing or repeatedly returns. Treatment may need to be delayed. Seek prompt medical advice if infection symptoms develop during therapy.
2. Tuberculosis
Patients should be evaluated for tuberculosis before the first dose. Latent tuberculosis must be managed according to medical advice, and anyone with possible exposure or symptoms such as persistent cough, weight loss, night sweats or fever should contact the treating team.
3. Vaccines
Live vaccines must not be given during treatment. Vaccination status should be reviewed before starting Ilumetri tildrakizumab. Ask the prescriber or pharmacist before any vaccine, including travel vaccines; non-live vaccines may still be considered according to individual guidance.
4. Allergic reactions
Stop using the medicine and seek urgent help for swelling of the face, lips, tongue or throat, difficulty breathing, widespread hives or severe dizziness. These may indicate a serious hypersensitivity reaction.
5. Pregnancy and breastfeeding
Women who are pregnant, planning pregnancy or breastfeeding should speak with the specialist before treatment. The decision requires an individual benefit-risk assessment. Do not stop or delay prescribed therapy without medical advice.
6. Other medicines and health conditions
Give the healthcare team a complete list of prescription medicines, over-the-counter products, supplements and biologic or immune-modifying treatments. Extra caution may be needed with medicines that affect immune function. The product information does not define a routine dose adjustment for older adults or for renal or hepatic impairment, but specialist assessment remains necessary.
7. Treatment response and appointments
Keep dermatology appointments so skin response, adverse effects and infections can be reviewed. The 28-week assessment helps the clinician decide whether continued treatment is appropriate.
Common side effects
The most commonly reported effects include upper respiratory tract infections. Headache, diarrhoea, gastroenteritis, back pain, nausea and injection-site pain can also occur. Most are not serious, but any severe, persistent or worrying symptom should be reported. Serious infection or a severe allergic reaction requires urgent assessment.
Storage and handling
Store Ilumetri tildrakizumab in a refrigerator at 2°C to 8°C, in the original carton to protect it from light. Do not freeze or shake. According to the current product information, an unopened syringe may be kept once at up to 25°C for a single period of no more than 30 days; once removed under this rule, it should not be returned to the refrigerator. Record the removal date and discard the syringe if the permitted time is exceeded. Keep it out of the sight and reach of children.
Frequently asked questions
Is Ilumetri the same as a steroid?
No. Ilumetri tildrakizumab is a targeted biologic antibody that blocks IL-23 p19. It is different from topical or systemic corticosteroids.
How quickly will it work?
Improvement varies between patients and usually develops over several weeks. Continue the prescribed schedule and let the dermatologist assess progress rather than changing treatment based on an early result.
Can I inject into a psoriasis plaque?
No. Choose unaffected skin and avoid areas that are tender, bruised, red, hard, thick or scaly. Rotate the site each time.
What if the syringe was frozen or shaken?
Do not use it. Contact the dispensing pharmacy or healthcare team for advice and replacement arrangements.
Where can I verify the medical information?
See the official European Medicines Agency Ilumetri overview and the current Ilumetri Summary of Product Characteristics. You can also browse related healthcare products on No Style Like.
Important medical disclaimer
Ilumetri tildrakizumab is prescription-only and must be initiated and monitored by a clinician experienced in plaque psoriasis. This page is educational and does not replace the approved leaflet, a diagnosis or personalised advice from a dermatologist or pharmacist. Never start, stop, change or share a prescription medicine without professional guidance.
Reviews
There are no reviews yet.